JCI Editorial Board first tier potential conflicts of interest

Aastrom Biosciences (S Emerson)

Aderans Research Institute (G Cotsarelis)

Aegerion Pharma (D Rader)

Astra Zeneca (D Rader)

Bosley Ince (G Cotsarelis)

Cytos Biotechnology (Y Choi)

Follica (G Cotsarelis)

Forbes Medi-tech (D Rader)

Fresenius Medical Care (S Goldfarb)

General Electric (S Goldfarb)

Genentech (B Grindlinger)

GlaxoSmithKline (D Rader, L Turka, K Honey)

Lilly (D Rader)

L’Oreal (G Cotsarelis)

Merck (R Collman, D Rader, J Weiser)

Metabolex, Inc. (M Birnbaum)

Motif Biosciences, Inc. (M Birnbaum)

Oncoceutics, Inc. (W El-Deiry)

Polymedix inc (S Goldfarb)

Takeda (D Rader)

Wyeth (K High, D Rader)